Delivery of oligonucleotides with lipid nanoparticles

Advanced Drug Delivery Reviews

Volumn 87, Issue , 2015, Pages 68-80

  Wang, Yuhua ^a   Miao, Lei ^a   Satterlee, Andrew ^a   Huang, Leaf ^a  

^a University of North Carolina   (United States)

Author keywords

Lipid nanoparticles; Lipoplexes; Liposome; Oligonucleotides; Systemic delivery

Indexed keywords

GENE EXPRESSION; LIPOSOMES; NANOPARTICLES; OLIGONUCLEOTIDES; TARGETED DRUG DELIVERY;

BROAD SPECTRUM; CHEMICAL AND PHYSICAL PROPERTIES; CLINICAL TRANSLATION; DRUG DELIVERY SYSTEM; LIPID NANOPARTICLES; LIPOPLEXES; SYSTEMIC DELIVERIES; TARGET CELLS;

CONTROLLED DRUG DELIVERY;

CATION; DETERGENT; LIPID; LIPOPLEX; LIPOSOME; NANOCOMPOSITE; NANOPARTICLE; OLIGONUCLEOTIDE; DRUG CARRIER;

CHEMICAL STRUCTURE; DIALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; EVAPORATION; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; LIVER DISEASE; LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; NONHUMAN; PHARMACOLOGICAL PROCEDURES; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; LIVER DISEASES; LUNG DISEASES; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; SURFACE PROPERTY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG LIBERATION; HUMANS; IMMUNOTHERAPY; LIPIDS; LIPOSOMES; LIVER DISEASES; LUNG DISEASES; NANOPARTICLES; OLIGONUCLEOTIDES; SURFACE PROPERTIES;

EID: 84937250770     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.02.007     Document Type: Review

References (134)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
2. Skutella T., Stohr T., Probst J.C., Ramalho-Ortigao F.J., Holsboer F., Jirikowski G.F. Antisense oligodeoxynucleotides for in vivo targeting of corticotropin-releasing hormone mRNA: comparison of phosphorothioate and 3'-inverted probe performance. Horm. Metab. Res. 1994, 26:460-464.
3. Souza P., Sedlackova L., Kuliszewski M., Wang J., Liu J., Tseu I., et al. Antisense oligodeoxynucleotides targeting PDGF-B mRNA inhibit cell proliferation during embryonic rat lung development. Development 1994, 120:2163-2173.
4. Biro S., Fu Y.M., Yu Z.X., Epstein S.E. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:654-658.
5. Young S.L., Krawczyk S.H., Matteucci M.D., Toole J.J. Triple helix formation inhibits transcription elongation in vitro. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:10023-10026.
6. Konopka K., Rossi J.J., Swiderski P., Slepushkin V.A., Duzgunes N. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim. Biophys. Acta 1998, 1372:55-68.
7. Brown S.A., Jarvis T.C. Optimization of lipid-mediated ribozyme delivery to cells in culture. Methods Mol. Biol. 1997, 74:441-449.
8. Kariko K., Megyeri K., Xiao Q., Barnathan E.S. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett. 1994, 352:41-44.
9. Dai W., Wang C., Wang F., Wang Y., Shen M., Chen K., et al. Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. Biochem. Biophys. Res. Commun. 2014, 446:541-548.
10. Meng W., Jiang L., Lu L., Hu H., Yu H., Ding D., et al. Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biol. Int. 2012, 36:653-659.
11. Ru P., Steele R., Hsueh E.C., Ray R.B. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer 2011, 2:720-727.
12. Kim T.G., Kim C.H., Won E.H., Bae S.M., Ahn W.S., Park J.B., et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 2004, 112:117-125.
13. Prince G.A., Mond J.J., Porter D.D., Yim K.C., Lan S.J., Klinman D.M. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol. 2003, 77:13156-13160.
14. Wilson A., Pitt B., Li S. Complex roles of CpG in liposomal delivery of DNA and oligonucleotides. Biosci. Rep. 2002, 22:309-322.
15. Kole R., Williams T., Cohen L. RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim. Pol. 2004, 51:373-378.
16. Mercatante D.R., Mohler J.L., Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem. 2002, 277:49374-49382.
17. Sazani P., Kole R. Modulation of alternative splicing by antisense oligonucleotides. Prog. Mol. Subcell. Biol. 2003, 31:217-239.
18. Loke S.L., Stein C.A., Zhang X.H., Mori K., Nakanishi M., Subasinghe C., et al. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:3474-3478.
19. Jones C.H., Chen C.K., Ravikrishnan A., Rane S., Pfeifer B.A. Overcoming nonviral gene delivery barriers: perspective and future. Mol. Pharm. 2013, 10:4082-4098.
20. Hsu C.Y., Uludag H. Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression. J. Drug Target. 2012, 20:301-328.
21. Bergen J.M., Pun S.H. Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons. J. Gene Med. 2008, 10:187-197.
22. Wiethoff C.M., Middaugh C.R. Barriers to nonviral gene delivery. J. Pharm. Sci. 2003, 92:203-217.
23. Nishikawa M., Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. 2001, 12:861-870.
24. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 2008, 26:561-569.
25. De Rosa G., De Stefano D., Laguardia V., Arpicco S., Simeon V., Carnuccio R., et al. Novel cationic liposome formulation for the delivery of an oligonucleotide decoy to NF-kappaB into activated macrophages. Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik eV 2008, 70:7-18.
26. Geary R.S., Leeds J.M., Fitchett J., Burckin T., Truong L., Spainhour C., et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos.: Biol. Fate Chem. 1997, 25:1272-1281.
27. Gokhale P.C., Soldatenkov V., Wang F.H., Rahman A., Dritschilo A., Kasid U. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther. 1997, 4:1289-1299.
28. Beisner J., Dong M., Taetz S., Piotrowska K., Kleideiter E., Friedel G., et al. Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA. J. Pharm. Sci. 2009, 98:1765-1774.
29. Yang X., Koh C.G., Liu S., Pan X., Santhanam R., Yu B., et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol. Pharm. 2009, 6:221-230.
30. Morille M., Passirani C., Vonarbourg A., Clavreul A., Benoit J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29:3477-3496.
31. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7413-7417.
32. Alexander M.Y., Akhurst R.J. Liposome-medicated gene transfer and expression via the skin. Hum. Mol. Genet. 1995, 4:2279-2285.
33. Remy J.S., Sirlin C., Vierling P., Behr J.P. Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjug. Chem. 1994, 5:647-654.
34. Gao X., Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 1991, 179:280-285.
35. Felgner J.H., Kumar R., Sridhar C.N., Wheeler C.J., Tsai Y.J., Border R., et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 1994, 269:2550-2561.
36. Lenssen K., Jantscheff P., von Kiedrowski G., Massing U. Combinatorial synthesis of new cationic lipids and high-throughput screening of their transfection properties. Chembiochem: Eur. J. Chem. Biol. 2002, 3:852-858.
37. Yuba E., Nakajima Y., Tsukamoto K., Iwashita S., Kojima C., Harada A., et al. Effect of unsaturated alkyl chains on transfection activity of poly(amidoamine) dendron-bearing lipids. J. Control. Release: Off. J. Control. Release Soc. 2012, 160:552-560.
38. Bennett C.F., Chiang M.Y., Chan H., Shoemaker J.E., Mirabelli C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 1992, 41:1023-1033.
39. Tormo M., Tari A.M., McDonnell T.J., Cabanillas F., Garcia-Conde J., Lopez-Berestein G. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk. Lymphoma 1998, 30:367-379.
40. Gutierrez-Puente Y., Tari A.M., Stephens C., Rosenblum M., Guerra R.T., Lopez-Berestein G. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J. Pharmacol. Exp. Ther. 1999, 291:865-869.
41. Stuart D.D., Allen T.M. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta 2000, 1463:219-229.
42. Pagnan G., Stuart D.D., Pastorino F., Raffaghello L., Montaldo P.G., Allen T.M., et al. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J. Natl. Cancer Inst. 2000, 92:253-261.
43. Pastorino F., Brignole C., Marimpietri D., Pagnan G., Morando A., Ribatti D., et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2003, 9:4595-4605.
44. Brignole C., Pastorino F., Marimpietri D., Pagnan G., Pistorio A., Allen T.M., et al. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl. Cancer Inst. 2004, 96:1171-1180.
45. Ropert C., Lavignon M., Dubernet C., Couvreur P., Malvy C. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem. Biophys. Res. Commun. 1992, 183:879-885.
46. Ma D.D., Wei A.Q. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk. Res. 1996, 20:925-930.
47. Li S.D., Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm. 2006, 3:579-588.
48. Love K.T., Mahon K.P., Levins C.G., Whitehead K.A., Querbes W., Dorkin J.R., et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1864-1869.
49. Dong Y., Love K.T., Dorkin J.R., Sirirungruang S., Zhang Y., Chen D., et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:3955-3960.
50. Capaccioli S., Di Pasquale G., Mini E., Mazzei T., Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem. Biophys. Res. Commun. 1993, 197:818-825.
51. Meidan V.M., Glezer J., Amariglio N., Cohen J.S., Barenholz Y. Oligonucleotide lipoplexes: the influence of oligonucleotide composition on complexation. Biochim. Biophys. Acta 2001, 1568:177-182.
52. Valencia P.M., Farokhzad O.C., Karnik R., Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat. Nanotechnol. 2012, 7:623-629.
53. Yu B., Zhu J., Xue W., Wu Y., Huang X., Lee L.J., et al. Microfluidic assembly of lipid-based oligonucleotide nanoparticles. Anticancer Res. 2011, 31:771-776.
54. Gershon H., Ghirlando R., Guttman S.B., Minsky A. Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. Biochemistry 1993, 32:7143-7151.
55. Gustafsson J., Arvidson G., Karlsson G., Almgren M. Complexes between cationic liposomes and DNA visualized by cryo-TEM. Biochim. Biophys. Acta 1995, 1235:305-312.
56. Sternberg B., Sorgi F.L., Huang L. New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. FEBS Lett. 1994, 356:361-366.
57. Radler J.O., Koltover I., Salditt T., Safinya C.R. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science 1997, 275:810-814.
58. Weisman S., Hirsch-Lerner D., Barenholz Y., Talmon Y. Nanostructure of cationic lipid-oligonucleotide complexes. Biophys. J. 2004, 87:609-614.
59. Remaut K., Lucas B., Braeckmans K., Sanders N.N., Demeester J., De Smedt S.C. Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopy. J. Control. Release: Off. J. Control. Release Soc. 2005, 110:212-226.
60. Zuhorn I.S., Hoekstra D. On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question?. J. Membr. Biol. 2002, 189:167-179.
61. Zuhorn I.S., Kalicharan R., Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J. Biol. Chem. 2002, 277:18021-18028.
62. Zabner J., Fasbender A.J., Moninger T., Poellinger K.A., Welsh M.J. Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. 1995, 270:18997-19007.
63. Zhou X., Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim. Biophys. Acta 1994, 1189:195-203.
64. Zelphati O., Szoka F.C. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 1996, 13:1367-1372.
65. Zelphati O., Szoka F.C. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11493-11498.
66. Allen T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 1994, 15:215-220.
67. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
68. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002, 62:6831-6836.
69. Semple S.C., Klimuk S.K., Harasym T.O., Dos Santos N., Ansell S.M., Wong K.F., et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta 2001, 1510:152-166.
70. Nakamura N., Timmermann S.A., Hart D.A., Kaneda Y., Shrive N.G., Shino K., et al. A comparison of in vivo gene delivery methods for antisense therapy in ligament healing. Gene Ther. 1998, 5:1455-1461.
71. Zelphati O., Zon G., Leserman L. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res. Dev. 1993, 3:323-338.
72. Weinstein J.N., Yoshikami S., Henkart P., Blumenthal R., Hagins W.A. Liposome-cell interaction: transfer and intracellular release of a trapped fluorescent marker. Science 1977, 195:489-492.
73. Szoka F., Magnusson K.E., Wojcieszyn J., Hou Y., Derzko Z., Jacobson K. Use of lectins and polyethylene glycol for fusion of glycolipid-containing liposomes with eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:1685-1689.
74. Huang R.T., Wahn K., Klenk H.D., Rott R. Fusion between cell membrane and liposomes containing the glycoproteins of influenza virus. Virology 1980, 104:294-302.
75. Straubinger R.M., Hong K., Friend D.S., Papahadjopoulos D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell 1983, 32:1069-1079.
76. Koltover I., Salditt T., Radler J.O., Safinya C.R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 1998, 281:78-81.
77. Thierry A.R., Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 1992, 20:5691-5698.
78. Thierry A.R., Dritschilo A. Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells. Ann. N. Y. Acad. Sci. 1992, 660:300-302.
79. Szoka F., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:4194-4198.
80. Szoka F., Olson F., Heath T., Vail W., Mayhew E., Papahadjopoulos D. Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim. Biophys. Acta 1980, 601:559-571.
81. Fresta M., Chillemi R., Spampinato S., Sciuto S., Puglisi G. Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression. J. Pharm. Sci. 1998, 87:616-625.
82. Semple S.C., Klimuk S.K., Harasym T.O., Hope M.J. Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol. 2000, 313:322-341.
83. Li W., Szoka F.C. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 2007, 24:438-449.
84. Akinc A., Goldberg M., Qin J., Dorkin J.R., Gamba-Vitalo C., Maier M., et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 2009, 17:872-879.
85. Zhang J., Fan H., Levorse D.A., Crocker L.S. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions. Langmuir 2011, 27:1907-1914.
86. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
87. Zhou W., Yuan X., Wilson A., Yang L., Mokotoff M., Pitt B., et al. Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug. Chem. 2002, 13:1220-1225.
88. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28:172-176.
89. Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 2010, 18:1357-1364.
90. Jayaraman M., Ansell S.M., Mui B.L., Tam Y.K., Chen J., Du X., et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. 2012, 51:8529-8533.
91. Maier M.A., Jayaraman M., Matsuda S., Liu J., Barros S., Querbes W., et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 2013, 21:1570-1578.
92. Gao X., Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996, 35:1027-1036.
93. Junghans M., Loitsch S.M., Steiniger S.C., Kreuter J., Zimmer A. Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides. Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik eV 2005, 60:287-294.
94. Ko Y.T., Bhattacharya R., Bickel U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J. Control. Release: Off. J. Control. Release Soc. 2009, 133:230-237.
95. Lee H.J., Engelhardt B., Lesley J., Bickel U., Pardridge W.M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 2000, 292:1048-1052.
96. Yang X., Peng Y., Yu B., Yu J., Zhou C., Mao Y., et al. A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery. Mol. Pharm. 2011, 8:709-715.
97. McMahon K.M., Mutharasan R.K., Tripathy S., Veliceasa D., Bobeica M., Shumaker D.K., et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 2011, 11:1208-1214.
98. Castanotto D., Stein C.A. Antisense oligonucleotides in cancer. Curr. Opin. Oncol. 2014, 26:584-589.
99. Gokhale P.C., Zhang C., Newsome J.T., Pei J., Ahmad I., Rahman A., et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2002, 8:3611-3621.
100. Rodrigueza W.V., Woolliscroft M.J., Ebrahim A.S., Forgey R., McGovren P.J., Endert G., et al. Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Cancer Chemother. Pharmacol. 2014, 74:151-166.
101. Griveau A., Bejaud J., Anthiya S., Avril S., Autret D., Garcion E. Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death. Int. J. Pharm. 2013, 454:765-774.
102. Siddiqui A., Gupta V., Liu Y.Y., Nazzal S. Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES). Int. J. Pharm. 2012, 431:222-229.
103. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
104. Elkins K.L., Rhinehart-Jones T.R., Stibitz S., Conover J.S., Klinman D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 1999, 162:2291-2298.
105. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 2004, 6:88-95.
106. Verthelyi D., Wang V.W., Lifson J.D., Klinman D.M. CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS 2004, 18:1003-1008.
107. Jiao X., Wang R.Y., Qiu Q., Alter H.J., Shih J.W. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J. Gen. Virol. 2004, 85:1545-1553.
108. Harandi A.M., Eriksson K., Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 2003, 77:953-962.
109. Wilson K.D., Raney S.G., Sekirov L., Chikh G., deJong S.D., Cullis P.R., et al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int. Immunopharmacol. 2007, 7:1064-1075.
110. Bramson J.L., Bodner C.A., Johnson J., Semple S., Hope M.J. Intravenous administration of stabilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells. Antisense Nucleic Acid Drug Dev. 2000, 10:217-224.
111. Takasaki J., Raney S.G., Chikh G., Sekirov L., Brodsky I., Tam Y., et al. Methods for the preparation of protein-oligonucleotide-lipid constructs. Bioconjug. Chem. 2006, 17:451-458.
112. Sato Y., Hatakeyama H., Sakurai Y., Hyodo M., Akita H., Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control. Release: Off. J. Control. Release Soc. 2012, 163:267-276.
113. Hatakeyama H., Murata M., Sato Y., Takahashi M., Minakawa N., Matsuda A., et al. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J. Control. Release: Off. J. Control. Release Soc. 2014, 173:43-50.
114. Ma Z., Zhang J., Alber S., Dileo J., Negishi Y., Stolz D., et al. Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. Am. J. Respir. Cell Mol. Biol. 2002, 27:151-159.
115. Griesenbach U., Kitson C., Escudero Garcia S., Farley R., Singh C., Somerton L., et al. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respir. Res. 2006, 7:26.
116. Stenton G.R., Kim M.K., Nohara O., Chen C.F., Hirji N., Wills F.L., et al. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J. Immunol. 2000, 164:3790-3797.
117. Ulanova M., Schreiber A.D., Befus A.D. The future of antisense oligonucleotides in the treatment of respiratory diseases. BioDrugs: Clin. Immunother. Biopharm. Gene Ther. 2006, 20:1-11.
118. Matsukura M., Koike K., Zon G. Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Toxicol. Lett. 1995, 82-83:435-438.
119. Goodchild J. Antisense antivirals. Antisense Res. Dev. 1991, 1:361-364.
120. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:280-284.
121. Deng Y.B., Nong L.G., Huang W., Pang G.G., Wang Y.F. Inhibition of hepatitis B virus (HBV) replication using antisense LNA targeting to both S and C genes in HBV. Chin. J. Hepatol. 2009, 17:900-904.
122. Soni P.N., Brown D., Saffie R., Savage K., Moore D., Gregoriadis G., et al. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology 1998, 28:1402-1410.
123. Cho C.W., Poo H., Cho Y.S., Cho M.C., Lee K.A., Lee S.J., et al. HPV E6 antisense induces apoptosis in CaSki cells via suppression of E6 splicing. Exp. Mol. Med. 2002, 34:159-166.
124. Clawson G.A., Miranda G.Q., Sivarajah A., Xin P., Pan W., Thiboutot D., et al. Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA. Gene Ther. 2004, 11:1331-1341.
125. Renneisen K., Leserman L., Matthes E., Schroder H.C., Muller W.E. Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. J. Biol. Chem. 1990, 265:16337-16342.
126. Zelphati O., Degols G., Loughrey H., Leserman L., Pompon A., Puech F., et al. Inhibition of HIV-1 replication in cultured cells with phosphorylated dideoxyuridine derivatives encapsulated in immunoliposomes. Antivir. Res. 1993, 21:181-195.
127. Anazodo M.I., Salomon H., Friesen A.D., Wainberg M.A., Wright J.A. Antiviral activity and protection of cells against human immunodeficiency virus type-1 using an antisense oligodeoxyribonucleotide phosphorothioate complementary to the 5'-LTR region of the viral genome. Gene 1995, 166:227-232.
128. Anazodo M.I., Wainberg M.A., Friesen A.D., Wright J.A. Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. J. Virol. 1995, 69:1794-1801.
129. Anazodo M.I., Wainberg M.A., Friesen A.D., Wright J.A. Inhibition of human immunodeficiency virus type 1 (HIV) gag gene expression by an antisense oligodeoxynucleotide phosphorothioate. Leukemia 1995, 9(Suppl. 1):S86-S88.
130. Abe T., Hatta T., Takai K., Nakashima H., Yokota T., Takaku H. Inhibition of influenza virus replication by phosphorothioate and liposomally endocapsulated oligonucleotides. Nucleosides Nucleotides 1998, 17:471-478.
131. Giannecchini S., Clausi V., Nosi D., Azzi A. Oligonucleotides derived from the packaging signal at the 5' end of the viral PB2 segment specifically inhibit influenza virus in vitro. Arch. Virol. 2009, 154:821-832.
132. Giannecchini S., Wise H.M., Digard P., Clausi V., Del Poggetto E., Vesco L., et al. Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules. Antivir. Res. 2011, 92:64-72.
133. Hatta T., Abe T., Takai K., Takaku H. Antisense nucleic acid therapy of influenza virus. Nihon Rinsho Jpn. J. Clin. Med. 1997, 55:2765-2771.
134. Wong J.P., Christopher M.E., Salazar A.M., Dale R.M., Sun L.Q., Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 2007, 25:3175-3178.